ImmunityBio, Inc. IBRX Reportable Segment — Total other expense, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — total other expense, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — total other expense, net?
- ImmunityBio, Inc. (IBRX) reported reportable segment — total other expense, net of -$563M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — total other expense, net changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — total other expense, net decreased by 759.9% year-over-year, from -$65.47M to -$563M.
- What does reportable segment — total other expense, net mean?
- The aggregate of all non-operating financial items, including interest, fair value adjustments, and other miscellaneous income or expenses. It provides a comprehensive view of the non-operating financial burden on the segment.